American Society of Clinical Oncology Guideline - site linked to picture
References
American Society of Clinical Oncology. (2018). MANAGEMENT OF IMMUNE-RELATED ADVERSE EVENTS IN PATIENTS TREATED WITH IMMUNE CHECKPOINT INHIBITOR THERAPY: AMERICAN SOCIETY OF CLINICAL ONCOLOGY CLINICAL PRACTICE GUIDELINE. https://old-prod.asco.org/sites/new-www.asco.org/files/content-files/practice-and-guidelines/2018-management-of-irAEs-summary.pdf
Castillo R, Richter M, Sandefur B, Thanarajasingam U. Retrospective Analysis of Patients Receiving Immune Checkpoint Inhibitors Presenting to the Emergency Department. Annals of Emerg Med. 2019. 74;4:311. doi: https://doi.org/10.1016/j.annemergmed.2019.08.270
Castillo RM, Sandefur BJ, Finch AS, Richter MD, Thanarajasingam U. Clinical Presentations and Outcomes of Patients Receiving Immune Checkpoint Inhibitors Presenting to the Emergency Department. Mayo Clin Proc Innov Qual Outcomes. 2021 Oct 30;5(6):1029-1035. doi: 10.1016/j.mayocpiqo.2021.09.007.
Chemotherapy to Treat Cancer (2022, Aug). National Cancer Institute. Retrieved January 27, 2024 from https://www.cancer.gov/about-cancer/treatment/types/chemotherapy
Immune Checkpoint Inhibitors (2022, Apr). National Cancer Institute. Retrieved January 21, 2024 from https://www.cancer.gov/about-cancer/treatment/types/chemotherapy
Majzoub I et al. Adverse Effects of Immune Checkpoint Therapy in Cancer Patients Visiting the Emergency Department of a Comprehensive Cancer Center. Annals of Emerg Med. 2019. doi: 10.1016/j.annemergmed.2018.04.019
Postow MA, Sidlow R, Hellmann MD. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. N Engl J Med. 2018 Jan 11;378(2):158-168. doi: 10.1056/NEJMra1703481. PMID: 29320654.
Schneider B et al. (2021). Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. Journal of Clinical Oncology. 39;36:4073-4125. doi: https://doi. org/10.1200/JCO.21. 01440
Castillo R, Richter M, Sandefur B, Thanarajasingam U. Retrospective Analysis of Patients Receiving Immune Checkpoint Inhibitors Presenting to the Emergency Department. Annals of Emerg Med. 2019. 74;4:311. doi: https://doi.org/10.1016/j.annemergmed.2019.08.270
Castillo RM, Sandefur BJ, Finch AS, Richter MD, Thanarajasingam U. Clinical Presentations and Outcomes of Patients Receiving Immune Checkpoint Inhibitors Presenting to the Emergency Department. Mayo Clin Proc Innov Qual Outcomes. 2021 Oct 30;5(6):1029-1035. doi: 10.1016/j.mayocpiqo.2021.09.007.
Chemotherapy to Treat Cancer (2022, Aug). National Cancer Institute. Retrieved January 27, 2024 from https://www.cancer.gov/about-cancer/treatment/types/chemotherapy
Immune Checkpoint Inhibitors (2022, Apr). National Cancer Institute. Retrieved January 21, 2024 from https://www.cancer.gov/about-cancer/treatment/types/chemotherapy
Majzoub I et al. Adverse Effects of Immune Checkpoint Therapy in Cancer Patients Visiting the Emergency Department of a Comprehensive Cancer Center. Annals of Emerg Med. 2019. doi: 10.1016/j.annemergmed.2018.04.019
Postow MA, Sidlow R, Hellmann MD. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. N Engl J Med. 2018 Jan 11;378(2):158-168. doi: 10.1056/NEJMra1703481. PMID: 29320654.
Schneider B et al. (2021). Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. Journal of Clinical Oncology. 39;36:4073-4125. doi: https://doi. org/10.1200/JCO.21. 01440
EMGuideWire
|
|
LEGAL DISCLAIMER (to make sure that we are all clear about this):The information on this website and podcasts are the opinions of the authors solely.
For Health Care Practitioners: This website and its associated products are provided only for medical education purposes. Although the editors have made every effort to provide the most up-to-date evidence-based medical information, this writing should not necessarily be considered the standard of care and may not reflect individual practices in other geographic locations.
For the Public: This website and its associated products are not intended to be a substitute for professional medical advice, diagnosis, or treatment. Your physician or other qualified health care provider should be contacted with any questions you may have regarding a medical condition. Do not disregard professional medical advice or delay seeking it based on information from this writing. Relying on information provided in this website and podcast is done at your own risk. In the event of a medical emergency, contact your physician or call 9-1-1 immediately.
For Health Care Practitioners: This website and its associated products are provided only for medical education purposes. Although the editors have made every effort to provide the most up-to-date evidence-based medical information, this writing should not necessarily be considered the standard of care and may not reflect individual practices in other geographic locations.
For the Public: This website and its associated products are not intended to be a substitute for professional medical advice, diagnosis, or treatment. Your physician or other qualified health care provider should be contacted with any questions you may have regarding a medical condition. Do not disregard professional medical advice or delay seeking it based on information from this writing. Relying on information provided in this website and podcast is done at your own risk. In the event of a medical emergency, contact your physician or call 9-1-1 immediately.